跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,462 条关于
“RELATIVITY-047”
全部
2,462
临床试验
1,383
药物
928
机构
6
资讯
145
上个月
BMS Launches India's First LAG-3-Based Dual Immunotherapy for Metastatic Melanoma
去年
BRAF Status and Response Kinetics Guide First-line Immunotherapy Selection in Advanced Melanoma
去年
Nivolumab/Relatlimab Combination Demonstrates Sustained Overall Survival Benefit in Advanced Melanoma
去年
BMS's Opdualag Shows Strong Early Performance as First LAG-3 Checkpoint Inhibitor for Melanoma
去年
Next-Generation Cancer Therapies: Advances in Checkpoint Inhibitors and Personalized Treatment
去年
LAG-3 Immunotherapies Market Poised for Explosive Growth with Next-Generation Therapies Advancing Across Major Markets
12个月前
FDA Clears First-in-Human Trial for LBL-047, Novel Bispecific Protein Targeting Autoimmune Diseases
8个月前
Leads Biolabs and Dianthus Therapeutics Initiate Phase 1 Trial of Novel Bifunctional Autoimmune Therapy LBL-047
去年
Surrozen's SZR-047 Meets Primary Endpoint in Phase III Trial for Muscle Disease
去年
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial for LAG-3 Inhibitor
第 1 页,共 15 页
上一页
下一页